Abstract:Ectopic breast tissue can occur anywhere along the primitive embryonic milk line and can be the site of the same pathologic processes found in the normal breast. Phyllodes tumor is an extremely rare fibroepithelial neoplasm that occurs in ectopic breast tissue of the vulva. To date, only 8 cases of phyllodes tumor in the vulva have been reported in the literature. This paper presents two additional case of benign phyllodes tumor in the vulva. The first patient was a 43-year-old woman, presenting with a lesion … Show more
“…Herein, we present a case of a benign appearing labial cyst which was pathologically determined to be consistent with a rare phyllodes tumour. Seventeen previously reported cases of vulvar phyllodes tumours have been reported in the literature2–12; however, our case represents the first reported tumour located in the labia minora. As these tumours are rarely found in the vulva, treatment and prognosis is less established13; we discuss the differential diagnosis, treatment and surveillance to be considered for these rare tumours.…”
A 33-year-old woman presented for a preoperative examination prior to an upcoming operative hysteroscopy. During the examination, a firm 1 cm mass in her right labia minora was noted. The mass was excised in the operating room without difficulty. Pathological examination revealed a benign phyllodes tumour of the vulva. Phyllodes tumours are uncommon fibroepithelial tumours primarily found in the breast although rarely may present as a vulvar lesion. Phyllodes tumours of the vulva are rarely reported in the literature, with only 17 previously reported cases. This case represents the first reported case of a phyllodes tumour occurring in the labia minora. While most of these tumours are benign, it is important to keep these and other rare tumours in the differential diagnosis of vulvar masses. Even with benign tumours, continued surveillance for recurrence should be performed.
“…Herein, we present a case of a benign appearing labial cyst which was pathologically determined to be consistent with a rare phyllodes tumour. Seventeen previously reported cases of vulvar phyllodes tumours have been reported in the literature2–12; however, our case represents the first reported tumour located in the labia minora. As these tumours are rarely found in the vulva, treatment and prognosis is less established13; we discuss the differential diagnosis, treatment and surveillance to be considered for these rare tumours.…”
A 33-year-old woman presented for a preoperative examination prior to an upcoming operative hysteroscopy. During the examination, a firm 1 cm mass in her right labia minora was noted. The mass was excised in the operating room without difficulty. Pathological examination revealed a benign phyllodes tumour of the vulva. Phyllodes tumours are uncommon fibroepithelial tumours primarily found in the breast although rarely may present as a vulvar lesion. Phyllodes tumours of the vulva are rarely reported in the literature, with only 17 previously reported cases. This case represents the first reported case of a phyllodes tumour occurring in the labia minora. While most of these tumours are benign, it is important to keep these and other rare tumours in the differential diagnosis of vulvar masses. Even with benign tumours, continued surveillance for recurrence should be performed.
“…Breast-like tumors of the vulva are rare. About 8 cases only of vulvar phyllodes tumors have been described [ 13 ]. Phyllodes tumors of the breast have been known to metastasize to other distant organs in the body but not to the vulvar area [ 14 ]; this case represents to the best of our knowledge the first reported case of a breast phyllodes tumor metastasizing to the vulvar area.…”
Phyllodes tumors of the breast are rare breast tumors that resemble fibroadenoma. They are composed of two types of tissues: stromal and glandular tissues. Unlike fibroadenoma, they are commonly found in the third decade of life and they tend to grow more rapidly. Depending on the relative components of the cells and mitotic activity, they are classified into benign, borderline, and malignant. They are usually present as a lump in the breast. Phyllodes tumors are usually managed by wide excision. The excision should be wide enough to ensure a tumor-free margin. Recurrence rate is very high and most recurrences are usually local. Metastasis to the vulva has not been reported.
“…Как и при патологии молочной железы, в аногенитальной области выделяют доброкачественные ЛО, пограничные (low grade) и злокачественные (high grade) [5]. В литературе описано всего 14 случаев доброкачественной ЛО аногенитальной области [46][47][48][49][50][51][52][53][54][55][56]. Подробная клинико-морфологическая характеристика ЛО АМПЖ представлена в таблице.…”
unclassified
“…При перианальном расположении узла возможно кровотечение из прямой кишки [25]. Описаны единичные случаи множественных ФА [11,13,18,37] и ЛО аногенитальной области [46,47,53]. Хирургическое удаление является радикальным методом лечения в большинстве слу-чаев.…”
unclassified
“…Клетки эпителиального компонента при иммуногистохимическом исследовании экспрессируют стероидные гормоны (ER, PR, AR), а также GCDFP-15, mammoglobin и маркеры, отражающие иммунофенотип эпителия молочной железы [11,22,26,31,53,55,60].…”
Mammary-like glands are a normal anatomical component of the anogenital region. The tumors occurring in them morphologically mimic the similar diseases of the breast. The paper presents a case of vulvar fibroadenoma with leaf-like outgrowths and apocrine metaplasia in a 38-year-old female patient. It describes the clinical and morphological characteristics of fibroadenomas and benign phyllodes tumors in the anogenital region.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.